CN112143767A - Method for preparing perinereis aibuhitensis protein source ACE inhibitory peptide - Google Patents
Method for preparing perinereis aibuhitensis protein source ACE inhibitory peptide Download PDFInfo
- Publication number
- CN112143767A CN112143767A CN202010856376.8A CN202010856376A CN112143767A CN 112143767 A CN112143767 A CN 112143767A CN 202010856376 A CN202010856376 A CN 202010856376A CN 112143767 A CN112143767 A CN 112143767A
- Authority
- CN
- China
- Prior art keywords
- protein
- nereis
- aibuhitensis
- ace inhibitory
- inhibitory peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 69
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 69
- 241000587741 Perinereis aibuhitensis Species 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 19
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 title claims abstract description 18
- 230000005764 inhibitory process Effects 0.000 claims abstract description 28
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 241000243827 Nereis Species 0.000 claims abstract description 22
- 108091005658 Basic proteases Proteins 0.000 claims abstract description 13
- 239000012528 membrane Substances 0.000 claims abstract description 12
- 239000012634 fragment Substances 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims description 23
- 239000000047 product Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 238000000108 ultra-filtration Methods 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 230000002255 enzymatic effect Effects 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000000413 hydrolysate Substances 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000005238 degreasing Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 239000012466 permeate Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 3
- 239000002220 antihypertensive agent Substances 0.000 abstract description 3
- 229940127088 antihypertensive drug Drugs 0.000 abstract description 3
- 208000006637 fused teeth Diseases 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract 2
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 230000002892 effect on hypertension Effects 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 238000012803 optimization experiment Methods 0.000 abstract 1
- 241000219226 Acer truncatum Species 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000965254 Apostichopus japonicus Species 0.000 description 2
- 235000000621 Bidens tripartita Nutrition 0.000 description 2
- 240000004082 Bidens tripartita Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- 241000680905 Alitta virens Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/10—Process efficiency
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Water Supply & Treatment (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a method for preparing perinereis aibuhitensis protein source ACE inhibitory peptide, which comprises the following steps: firstly, obtaining the optimal conditions for extracting the ACE inhibitory peptide of the double-tooth-tail nereis protein source through a single-factor experiment and an orthogonal optimization experiment, wherein the results show that the alkaline protease hydrolyzes the nereis protein to obtain the optimal pH value, temperature and solid-liquid ratio of the ACE inhibitory peptide. Meanwhile, the clam worm zymolyte is separated into inhibitory peptides with different molecular weight fragments by a membrane separation technology, and the most active molecular weight fragment is selected. Finally, the inhibition rate of the extracted inhibition peptide fragment of the Nereis bidentate Nereis dubia on ACE is determined. The experiment proves that the food-borne antihypertensive peptide has good inhibition effect on hypertension, and can be used for developing antihypertensive drugs which can be put into the market.
Description
Technical Field
The invention belongs to the technical field of food processing, and particularly relates to a method for preparing perinereis aibuhitensis protein source ACE inhibitory peptide.
Background
The RMB spent in China for treating hypertension is nearly 500 million yuan per year, which is only lower than the cost spent in apoplexy. Chemically synthesized antihypertensive drugs such as captopril, aliskiren, losartan and the like have obvious curative effect on treatment of hypertension, but the side effects of the drugs are also obvious, such as rash, proteinuria and the like, and drug dependence can also occur. However, antihypertensive peptides extracted from natural plants, animals and microorganisms have some advantages not possessed by chemically synthesized antihypertensive drugs: firstly, the curative effect is obvious, the blood pressure control effect on patients is obvious, and the effect on normal patients is not influenced; secondly, the safety is high, and the antihypertensive peptide is food-grade enzyme prepared by enzymolysis of food by protease under mild conditions and does not contain chemical synthesis reagents and additives; then, the application is wide, and the natural polypeptide in the food has the effects of reducing blood pressure, preventing tumor, treating blood coagulation and improving immunity; finally, the potential is great, and the ACE inhibitory peptide has better water solubility, so that the ACE inhibitory peptide can be easily added into various existing health care products in the market, and the health care effect of the health care products is improved.
Nereid is a soft invertebrate, and is generally called as scolopendra, Shuibao and the like. The variety of the clamworms in China is rich, more than eighty types exist, and the clamworms are intensively distributed in the east coastal area of China. The Nereid has high nutritive value, rich fat and protein, and multiple minerals and vitamins. Nereid is a traditional marine Chinese medicine, can improve dry mouth and throat, eliminate swelling and pain, remove toxic sores and repair damaged skin, and is known as cordyceps sinensis in the sea. The Chinese invention patent CN201810668300.5 discloses a preparation method of acer truncatum seed active peptide, which is characterized in that acer truncatum seed protein is extracted by ultrasonic assistance, and the acer truncatum seed protein is hydrolyzed by using Alcalase protease to prepare the acer truncatum seed active peptide. Chinese patent CN201811214660.4 discloses an ACE inhibitory active peptide derived from stichopus japonicus, which is prepared by performing enzymolysis on stichopus japonicus by using compound protease, separating by using an ultrafiltration membrane, and separating and purifying by using column chromatography and high performance liquid chromatography to obtain a better ACE inhibitory active peptide. The content of the nereis virens protein is very high, but more applications in baits exist at present, and no report on the separation and purification of the ACE inhibitory active peptide from the perinereis aibuhitensis protein is reported at present.
Disclosure of Invention
The invention aims to solve the defects of the prior art and provides a method for preparing ACE inhibitory peptide of periceella aibuhitensis protein source, which comprises the steps of extracting the nereis aibuhitensis protein by using an alkali extraction and acid precipitation method, hydrolyzing the nereis aibuhitensis protein by using alkaline protease, optimizing single factors such as solid-to-liquid ratio, enzymolysis pH value and enzymolysis temperature, determining hydrolysis conditions, and performing ultrafiltration on fragments after enzymolysis to obtain the polypeptide with the optimal ACE inhibitory effect.
The invention relates to a method for preparing perinereis aibuhitensis protein source ACE inhibitory peptide, which comprises the following steps:
(1) crushing clamworm and carrying out degreasing treatment;
(2) and (3) extraction of nereis proteins: leaching the pretreated defatted perinereis aibuhitensis powder for 60min by using 1mol/L diluted alkali solution, controlling the temperature at 50-60 ℃, adjusting the pH to 8, centrifuging to remove insoluble substances at the bottom layer, taking supernatant, adjusting the pH to the isoelectric point of perinereis aibuhitensis protein by using hydrochloric acid, standing to ensure that the protein is fully aggregated to preliminarily form precipitate, centrifuging again, filtering to remove the supernatant to obtain precipitated protein, repeatedly adding the precipitate with the pH of 4.5 into distilled water for washing, adjusting the pH of the precipitate to 7.0, fully pre-freezing the obtained precipitated protein, drying the precipitated protein to constant weight by using a freeze-drying method in a freeze-drying machine to obtain perinereis aibuhitensis protein freeze-dried powder, and freezing for later use;
(3) carrying out enzymolysis treatment on nereis protein: weighing nereis protein freeze-dried powder, selecting alkaline protease to prepare an enzymatic hydrolysate, hydrolyzing the nereis protein freeze-dried powder for 4 hours, inactivating enzymes at high temperature after the hydrolysis is finished, centrifuging to obtain a supernatant, and detecting the ACE inhibition rate of each enzymolysis product, wherein the higher the inhibition rate is, the better the enzymolysis effect is;
(4) screening high-activity molecular weight fragments: and (4) passing the centrifuged enzymatic hydrolysate through an ultrafiltration membrane to obtain separation products with different molecular masses.
In a preferable embodiment of the present invention, when the alkaline protease in the step (3) hydrolyzes the nereis protein, the solid-to-liquid ratio is 1:6 to 1:14 g/mL.
In a preferred embodiment of the present invention, when the alkaline protease in the step (3) hydrolyzes the nereis protein, the pH of the enzymatic hydrolysate is 6 to 14, and more preferably 6 to 12.
As a preferable scheme of the invention, when the alkaline protease in the step (3) hydrolyzes the nereis protein, the enzymolysis temperature is 40-60 ℃.
As a preferable scheme of the invention, when the enzymolysis liquid in the step (4) permeates the ultrafiltration membrane, the size of the ultrafiltration membrane is 1-10 kDa.
Advantageous effects
At present, no report exists for preparing ACE inhibitory active peptide from perinereis aibuhitensis protein. Nereid protein content is very high, but has been used more in bait applications before. The method takes perinereis aibuhitensis protein as a raw material, extracts the nereis aibuhitensis protein by an alkali extraction and acid precipitation method, hydrolyzes the nereis aibuhitensis protein by alkali protease, and obtains the polypeptide with ACE inhibitory activity by an ultrafiltration method, and the method has the advantages of simple extraction method and high application value.
Drawings
FIG. 1 shows the effect of different solid-liquid ratios on ACE inhibition of a double-tooth tail nereis protein source;
FIG. 2 is the influence of different pH values of the enzymatic hydrolysate on the ACE inhibition rate of the Nereid protein source;
FIG. 3 shows the effect of different enzymolysis temperatures on ACE inhibition ratio of a double-tooth tail silkworm protein source.
Detailed Description
The present invention will be described in further detail with reference to examples. The reagents or instruments used are not indicated by manufacturers, and are regarded as conventional products which can be purchased in the market.
Example 1
(1) Crushing clamworm and carrying out degreasing treatment;
(2) and (3) extraction of nereis proteins: leaching the pretreated defatted perinereis aibuhitensis powder with 1mol/L diluted alkali solution for 60min, controlling the temperature at 50-60 deg.C, adjusting pH to 8, centrifuging for 15min by using a refrigerated centrifuge to remove insoluble substances at the bottom layer, continuously stirring supernatant, simultaneously adding 1mol/L hydrochloric acid into the solution to adjust the pH value to 4.5, standing for 30min to ensure that the protein is fully coagulated to form a precipitate primarily, centrifuging for 15min by using a refrigerated centrifuge again, filtering to remove supernatant to obtain precipitated protein, repeatedly adding the precipitate with the pH value of 4.5 into distilled water for washing, adjusting the pH value of the precipitate to 7.0, fully pre-freezing the obtained precipitated protein, drying the precipitated protein in a freeze dryer by using a freeze-drying method to constant weight to obtain peribalanus bidentate nereis protein freeze-dried powder, and freezing in a freezing chamber at-18 ℃ in a refrigerator for later use;
(3) carrying out enzymolysis treatment on nereis protein: weighing nereis protein freeze-dried powder, selecting alkaline protease, preparing into enzymolysis liquid with a solid-to-liquid ratio of 1:6g/mL and a pH value of 6, carrying out enzymolysis at 60 ℃, hydrolyzing the nereis protein freeze-dried powder for 4h, carrying out high-temperature enzyme deactivation after the hydrolysis is finished, then putting the solution into a refrigerated centrifuge, regulating the rotating speed of the refrigerated centrifuge to 5000r/min, setting the time to 15min, centrifuging, and taking supernatant;
(4) screening high-activity molecular weight fragments: and (3) allowing the centrifuged enzymatic hydrolysate to pass through a 10kDa ultrafiltration membrane to obtain a separated product with the ultrafiltrate of less than 10kDa molecular mass, and detecting the ACE inhibition effect of the separated product, wherein the ACE inhibition rate is 58.3%.
Example 2
The same as example 1, except that the solid-to-liquid ratio in the step (3) is 1:14g/mL, the pH value is 7, and the enzymolysis temperature is 40 ℃; and (4) allowing the centrifuged enzymatic hydrolysate to pass through a 1kDa ultrafiltration membrane to obtain a separated product with the ultrafiltrate of less than 1kDa molecular mass, wherein the ACE inhibition rate of the separated product is 67.4%.
Example 3
The same as example 1, except that the solid-to-liquid ratio in the step (3) is 1:8g/mL, the pH value is 9, and the enzymolysis temperature is 45 ℃; and (4) allowing the centrifuged enzymolysis liquid to penetrate through a 3kDa ultrafiltration membrane to obtain a separated product with the ultrafiltrate of which the molecular mass is less than 3kDa, wherein the ACE inhibition rate of the separated product is 60.3%.
Example 4
The same as example 1, except that the solid-to-liquid ratio in the step (3) is 1:10g/mL, the pH value is 11, and the enzymolysis temperature is 55 ℃; and (4) allowing the centrifuged enzymatic hydrolysate to pass through a 3kDa ultrafiltration membrane to obtain a separated product with the ultrafiltrate of less than 3kDa molecular mass, wherein the ACE inhibition rate of the separated product is 63.7%.
Example 5
The same as example 1, different from example 1, in the step (3), the solid-to-liquid ratio is 1:12g/mL, the pH value is 12, the enzymolysis temperature is 50 ℃, and the ACE inhibition rate of the finally obtained separation product is 55.2%.
Evaluation of Performance
A. The single-factor test optimizes the preparation process of the ACE inhibitory peptide.
(1) Effect of solid-liquid ratio on ACE inhibition ratio
Taking 5 clean test tubes, respectively labeling, adding 1g of peribalanus bidentate nereis protein freeze-dried powder, respectively performing enzymolysis for 45min by using alkaline protease under the conditions that the pH =10 and the temperature is 50 ℃, wherein the solid-to-liquid ratio is 1:6g/mL, 1:8g/mL, 1:10g/mL, 1:12g/mL and 1:14g/mL, centrifuging and filtering for 15min, collecting supernatant, and respectively determining the ACE inhibition rate.
(2) Influence of pH value of enzymolysis liquid on ACE inhibition rate
Taking 5 clean test tubes, respectively labeling, adding 1g of Perinereis aibuhitensis protein freeze-dried powder, performing enzymolysis for 45min by using alkaline protease at the temperature of 50 ℃ and under the condition that the solid-to-liquid ratio is 1:10g/mL, respectively, centrifuging and filtering for 15min, collecting supernatant, and respectively determining the ACE inhibition rate.
(3) Effect of enzymolysis temperature on ACE inhibition ratio
Taking 5 clean test tubes, respectively labeling, adding 1g of Perinereis aibuhitensis protein freeze-dried powder, respectively performing enzymolysis at 40 ℃, 45 ℃, 50 ℃, 55 ℃ and 60 ℃ for 45min under the conditions that the pH =10 and the solid-to-liquid ratio is 1:10g/mL, centrifuging and filtering for 15min, collecting supernatant, and respectively determining the ACE inhibition rate.
FIG. 1 shows that when the solid-liquid ratio is 1: 6-1: 14g/mL, the ACE inhibition rate firstly rises and then falls along with the rise of the solid-liquid ratio, and reaches the highest value when the solid-liquid ratio is 1:10 g/mL.
FIG. 2 shows that pH can affect the spatial structure of the enzyme, even denature the enzyme in severe cases, and the change of the enzyme activity can affect the enzymolysis effect and further affect the ACE inhibition rate. When the pH value of the enzymolysis liquid is 6-14, the ACE inhibition rate firstly rises and then falls along with the rise of the pH, and the ACE inhibition rate is highest when the pH is = 10.
FIG. 3 shows that the enzyme is a protein with a catalytic effect, the enzyme structure is damaged by overhigh temperature, the enzyme activity is reduced, the enzymolysis effect is reduced by the reduction of the enzyme activity, and the ACE inhibition rate is finally influenced. When the enzymolysis temperature is between 40 ℃ and 60 ℃, the ACE inhibition rate firstly rises and then falls along with the rise of the temperature, and reaches the highest value when the temperature is 50 ℃.
The foregoing is illustrative of the preferred embodiments of the present invention only and is not intended to limit the process of the present invention in any way. According to the preparation method of the perinereis aibuhitensis protein source ACE inhibitory peptide, the perinereis aibuhitensis protein source ACE inhibitory peptide can be prepared under the condition that the pH value of the enzymolysis liquid in the step (3) is 14. The protection of the present invention is not limited to the above embodiments. Variations and advantages that may occur to those skilled in the art may be incorporated into the invention without departing from the spirit and scope of the inventive concept and the scope of the appended claims is intended to be protected.
Claims (5)
1. A method for preparing perinereis aibuhitensis protein source ACE inhibitory peptide comprises the following steps:
(1) crushing clamworm and carrying out degreasing treatment;
(2) and (3) extraction of nereis proteins: leaching the pretreated defatted perinereis aibuhitensis powder for 60min by using 1mol/L diluted alkali solution, controlling the temperature at 50-60 ℃, adjusting the pH to 8, then centrifuging to remove insoluble substances at the bottom layer, taking supernatant, adjusting the pH to the isoelectric point of perinereis aibuhitensis protein by using hydrochloric acid, standing to ensure that the protein is fully aggregated and then preliminarily forms precipitate, centrifuging again and filtering to remove the supernatant to obtain precipitated protein, then repeatedly adding the precipitate with the pH of 4.5 into distilled water for washing, adjusting the pH of the precipitate to 7.0, fully pre-freezing the obtained precipitated protein, then putting the precipitate protein into a freeze-drying machine, drying the precipitated protein to constant weight by using a freeze-drying method to obtain freeze-dried perinereis aibuhitensis protein powder for later use;
(3) carrying out enzymolysis treatment on nereis protein: weighing nereis protein freeze-dried powder, selecting alkaline protease to prepare an enzymatic hydrolysate, hydrolyzing the nereis protein freeze-dried powder for 4 hours, inactivating enzymes at high temperature after the hydrolysis is finished, centrifuging to obtain a supernatant, and detecting the ACE inhibition rate of each enzymolysis product, wherein the higher the inhibition rate is, the better the enzymolysis effect is;
(4) screening high-activity molecular weight fragments: and (4) passing the centrifuged enzymatic hydrolysate through an ultrafiltration membrane to obtain separation products with different molecular masses.
2. The method for preparing an ACE inhibitory peptide derived from perinereis aibuhitensis protein according to claim 1, wherein the solid-to-liquid ratio is 1: 6-1: 14g/mL when the Nereis aibuhitensis protein is hydrolyzed by the alkaline protease in the step (3).
3. The method for preparing ACE inhibitory peptide of perinereis aibuhitensis protein source according to claim 1, wherein when alkaline protease in the step (3) hydrolyzes Nereis aibuhitensis protein, the pH value of enzymolysis liquid is 6-14.
4. The method for preparing ACE inhibitory peptide of Perinereis aibuhitensis protein source according to claim 1, wherein the enzymolysis temperature is 40-60 ℃ when alkaline protease in the step (3) hydrolyzes Nereis aibuhitensis protein.
5. The method for preparing the ACE inhibitory peptide of the perinereis aibuhitensis protein source according to claim 1, wherein when the enzymatic hydrolysate in the step (4) permeates through the ultrafiltration membrane, the size of the ultrafiltration membrane is 1-10 kDa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010856376.8A CN112143767B (en) | 2020-08-24 | 2020-08-24 | Manufacturing method of perinereis aibuhitensis protein source ACE inhibitory peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010856376.8A CN112143767B (en) | 2020-08-24 | 2020-08-24 | Manufacturing method of perinereis aibuhitensis protein source ACE inhibitory peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112143767A true CN112143767A (en) | 2020-12-29 |
| CN112143767B CN112143767B (en) | 2023-05-26 |
Family
ID=73889044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010856376.8A Active CN112143767B (en) | 2020-08-24 | 2020-08-24 | Manufacturing method of perinereis aibuhitensis protein source ACE inhibitory peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112143767B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113430239A (en) * | 2021-07-07 | 2021-09-24 | 莱阳六和饲料有限公司 | Polypeptide feed for improving growth and immunity of stichopus japonicus |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106636273A (en) * | 2016-11-28 | 2017-05-10 | 浙江海洋大学 | A preparing method of a perinereis aibuhitensis anticoagulation peptide |
| CN106755230A (en) * | 2016-11-28 | 2017-05-31 | 浙江海洋大学 | A kind of preparation method of perinereis aibihitensis Grube anti-lung cancer polypeptide |
-
2020
- 2020-08-24 CN CN202010856376.8A patent/CN112143767B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106636273A (en) * | 2016-11-28 | 2017-05-10 | 浙江海洋大学 | A preparing method of a perinereis aibuhitensis anticoagulation peptide |
| CN106755230A (en) * | 2016-11-28 | 2017-05-31 | 浙江海洋大学 | A kind of preparation method of perinereis aibihitensis Grube anti-lung cancer polypeptide |
Non-Patent Citations (1)
| Title |
|---|
| LI CHEN等: "Preparation of an ACE-inhibitory peptide from Perinereis aibuhitensis protein", 《BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113430239A (en) * | 2021-07-07 | 2021-09-24 | 莱阳六和饲料有限公司 | Polypeptide feed for improving growth and immunity of stichopus japonicus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112143767B (en) | 2023-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109943615B (en) | Method for preparing active peptide by using euphausia superba powder | |
| US20110070608A1 (en) | Method for Producing Corn Gluten Hydrolysate and Corn Gluten Hydrolysate Using the Same | |
| JPH05505304A (en) | Method for producing enzymatic hydrolyzate | |
| JPH0458946B2 (en) | ||
| CN101275156A (en) | Collagen bioactive peptide, preparation and use thereof | |
| CN108477619A (en) | A kind of preparation method of compound amino acid chelate calcium | |
| CLEGG et al. | Dietary enzymic hydrolysates of protein with reduced bitterness | |
| CN113088548A (en) | Preparation method of oyster antioxidant active peptide | |
| CN110240626A (en) | A kind of quinoa polysaccharide polypeptide production method | |
| CN100496277C (en) | Mantis shrimp protein pulp and its producing process | |
| JPS5854786B2 (en) | Method for producing protein hydrolyzate from whey protein | |
| CN112143767A (en) | Method for preparing perinereis aibuhitensis protein source ACE inhibitory peptide | |
| CN104928339B (en) | A kind of preparation method with the oat protein peptide for inhibiting intestinal inflammatory activity | |
| CN108517344A (en) | A kind of preparation method of ginseng peptide | |
| CN107529554A (en) | A kind of production technology of pig blood ball peptide | |
| WO2010044688A1 (en) | A method of producing peptide preparations for oral administration | |
| CN106086137A (en) | A kind of method utilizing Crusta Penaeus seu Panulirus to prepare anti-oxidation peptide | |
| CN106978460B (en) | Method for preparing bioactive peptide by enzymolysis of decapterus maruadsi processing byproduct | |
| Ledward et al. | Recovery and utilisation of by‐product proteins of the meat industry | |
| CN109234342A (en) | The preparation method of turtle peptide | |
| RU2272808C2 (en) | Method for preparing collagen | |
| US20030022274A1 (en) | Partially hydrolysed protein nutrient supplement | |
| US5444046A (en) | Amylase inhibitors | |
| CN108486201B (en) | Method for extracting bioactive polypeptide of ginkgo | |
| CN110241163A (en) | A kind of method that alkali carries-embrane method extracts quinoa polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231228 Address after: 271000 first road, electromechanical Industrial Park, Shandong Daiyue Economic Development Zone, Tai'an City, Shandong Province Patentee after: Shandong Jusheng Biotechnology Co.,Ltd. Address before: Room 101, Building H, 237 Loumen Road, Industrial Park, Suzhou City, Jiangsu Province, 215000 Patentee before: Suzhou 30 billion Technology Co.,Ltd. Effective date of registration: 20231228 Address after: Room 101, Building H, 237 Loumen Road, Industrial Park, Suzhou City, Jiangsu Province, 215000 Patentee after: Suzhou 30 billion Technology Co.,Ltd. Address before: 224051 middle road of hope Avenue, Yancheng City, Jiangsu Province, No. 1 Patentee before: YANCHENG INSTITUTE OF TECHNOLOGY |